Bixalomer
PreclinicalSmall molecule
AstellasBixalomer is one of 51 small molecule programs targeting Hyperphosphatemia. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
540 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Lorelco
SanofiPreclinical
Activase
RochePreclinical
Epoetin Beta
RochePreclinical
Sodium Valproate
AstraZenecaPreclinical
PROCRIT
WWim Janssens
Preclinical
Tradjenta
Boehringer IngelheimPreclinical
Verquvo
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Singulair
OOrganon and Co
Preclinical
Ativan
BBausch Health Americas, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bixalomer. EMBL-EBI & Wellcome Sanger Institute.
- [4]